In certain autosomal recessive disorders, there is suggestive evidence that heterozygous carriers may have some selective advantage over normal homozygotes. These include, for example, cystic fibrosis, Tay-Sachs disease and phenylketonuria. The best example so far, however, is that of significant heterozygous advantage in sickle-cell anaemia with increased resistance to falciparum malaria. [1] How a possible heterozygous advantage can be calculated has been detailed. [2] More recently, the possibility of heterozygous advantage has been suggested in the case of a rare autosomal recessive form of congenital muscular dystrophy (MDC1D). [3] This disorder is caused by the mutation LARGE, in the gene locus at 22q12, which results in reduced glycosylation of α-dystroglycan, a protein located outside the muscle basement membrane (basal lamina) (Fig. 1) . [4] The extracellular protein α-dystroglycan is known to bind to various extracellular proteins (perlecan, agrin and laminins). [5] But most importantly, from the present point of view, α-dystroglycan provides a receptor for various pathogenic viruses, and this depends on effective glycosylation. There have been several recent reports detailing this molecular mechanism. [6] [7] [8] [9] The defective and reduced glycosylation in MDC1D might therefore be expected to affect its function as a receptor for several viruses including Lassa fever and other arenaviruses. [10] In fact, glycosylation defects in fibroblasts are associated with resistance to murine leukaemia virus. [11] Those disorders that could be relevant in the present context include many haemorrhagic viral diseases in Central Africa, South America and India, which have been described in detail by Garrett [12] and Karlen. [13] These haemorrhagic diseases all present with internal bleeding, shock and the majority of patients succumb, though a few do survive. These diseases include Ebola fever, of which there has recently been an outbreak in West Africa. The question therefore is: could heterozygotes for α-dystroglycan LARGE mutations be in any way resistant to these diseases? Could this be tested for by determining heterozygosity in those who succumb to the disease and those who survive?
Such studies would not have to be confined to one disorder but to any of the haemorrhagic disorders. Furthermore, screening for any other defects in α-dystroglycan could be revealing even if unrelated to congenital muscular dystrophy, which is presumably rare in such populations anyway. In certain autosomal recessive disorders there is suggestive evidence that heterozygous carriers may have some selective advantage over normal homozygotes. These include, for example, cystic fibrosis, Tay-Sachs disease and phenylketonuria. The best example so far, however, is that of significant heterozygous advantage in sickle-cell anaemia with increased resistance to falciparum malaria. 
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